1491 related articles for article (PubMed ID: 30208454)
1. Effect of Piperacillin-Tazobactam vs Meropenem on 30-Day Mortality for Patients With E coli or Klebsiella pneumoniae Bloodstream Infection and Ceftriaxone Resistance: A Randomized Clinical Trial.
Harris PNA; Tambyah PA; Lye DC; Mo Y; Lee TH; Yilmaz M; Alenazi TH; Arabi Y; Falcone M; Bassetti M; Righi E; Rogers BA; Kanj S; Bhally H; Iredell J; Mendelson M; Boyles TH; Looke D; Miyakis S; Walls G; Al Khamis M; Zikri A; Crowe A; Ingram P; Daneman N; Griffin P; Athan E; Lorenc P; Baker P; Roberts L; Beatson SA; Peleg AY; Harris-Brown T; Paterson DL;
JAMA; 2018 Sep; 320(10):984-994. PubMed ID: 30208454
[TBL] [Abstract][Full Text] [Related]
2. Meropenem versus piperacillin-tazobactam for definitive treatment of bloodstream infections due to ceftriaxone non-susceptible Escherichia coli and Klebsiella spp (the MERINO trial): study protocol for a randomised controlled trial.
Harris PN; Peleg AY; Iredell J; Ingram PR; Miyakis S; Stewardson AJ; Rogers BA; McBryde ES; Roberts JA; Lipman J; Athan E; Paul SK; Baker P; Harris-Brown T; Paterson DL
Trials; 2015 Jan; 16():24. PubMed ID: 25623485
[TBL] [Abstract][Full Text] [Related]
3. Effect of Meropenem-Vaborbactam vs Piperacillin-Tazobactam on Clinical Cure or Improvement and Microbial Eradication in Complicated Urinary Tract Infection: The TANGO I Randomized Clinical Trial.
Kaye KS; Bhowmick T; Metallidis S; Bleasdale SC; Sagan OS; Stus V; Vazquez J; Zaitsev V; Bidair M; Chorvat E; Dragoescu PO; Fedosiuk E; Horcajada JP; Murta C; Sarychev Y; Stoev V; Morgan E; Fusaro K; Griffith D; Lomovskaya O; Alexander EL; Loutit J; Dudley MN; Giamarellos-Bourboulis EJ
JAMA; 2018 Feb; 319(8):788-799. PubMed ID: 29486041
[TBL] [Abstract][Full Text] [Related]
4. Clinical outcomes in patients with piperacillin/tazobactam-non-susceptible but ceftriaxone-susceptible E. coli or K. pneumoniae bloodstream infection.
Mourad A; Smith AG; Troy JD; Holland TL; Wrenn RH; Turner NA
J Antimicrob Chemother; 2024 Jun; 79(6):1456-1461. PubMed ID: 38708907
[TBL] [Abstract][Full Text] [Related]
5. Carbapenem therapy is associated with improved survival compared with piperacillin-tazobactam for patients with extended-spectrum β-lactamase bacteremia.
Tamma PD; Han JH; Rock C; Harris AD; Lautenbach E; Hsu AJ; Avdic E; Cosgrove SE;
Clin Infect Dis; 2015 May; 60(9):1319-25. PubMed ID: 25586681
[TBL] [Abstract][Full Text] [Related]
6. Appropriate non-carbapenems are not inferior to carbapenems as initial empirical therapy for bacteremia caused by extended-spectrum beta-lactamase-producing Enterobacteriaceae: a propensity score weighted multicenter cohort study.
Ko JH; Lee NR; Joo EJ; Moon SY; Choi JK; Park DA; Peck KR
Eur J Clin Microbiol Infect Dis; 2018 Feb; 37(2):305-311. PubMed ID: 29177611
[TBL] [Abstract][Full Text] [Related]
7. In vitro and in vivo activities of piperacillin-tazobactam and meropenem at different inoculum sizes of ESBL-producing Klebsiella pneumoniae.
Harada Y; Morinaga Y; Kaku N; Nakamura S; Uno N; Hasegawa H; Izumikawa K; Kohno S; Yanagihara K
Clin Microbiol Infect; 2014 Nov; 20(11):O831-9. PubMed ID: 24813594
[TBL] [Abstract][Full Text] [Related]
8. Extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae bacteremia in febrile neutropenic children.
Han SB; Jung SW; Bae EY; Lee JW; Lee DG; Chung NG; Jeong DC; Cho B; Kang JH; Kim HK; Park YJ
Microb Drug Resist; 2015 Apr; 21(2):244-51. PubMed ID: 25398058
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of ceftolozane/tazobactam against urinary tract and intra-abdominal infections caused by ESBL-producing Escherichia coli and Klebsiella pneumoniae: a pooled analysis of Phase 3 clinical trials.
Popejoy MW; Paterson DL; Cloutier D; Huntington JA; Miller B; Bliss CA; Steenbergen JN; Hershberger E; Umeh O; Kaye KS
J Antimicrob Chemother; 2017 Jan; 72(1):268-272. PubMed ID: 27707990
[TBL] [Abstract][Full Text] [Related]
10. No association between resistance mutations, empiric antibiotic, and mortality in ceftriaxone-resistant Escherichia coli and Klebsiella pneumoniae bacteremia.
Heng ST; Chen SL; Wong JGX; Lye DC; Ng TM
Sci Rep; 2018 Aug; 8(1):12785. PubMed ID: 30143706
[TBL] [Abstract][Full Text] [Related]
11. Empiric Piperacillin-Tazobactam versus Carbapenems in the Treatment of Bacteraemia Due to Extended-Spectrum Beta-Lactamase-Producing Enterobacteriaceae.
Ng TM; Khong WX; Harris PN; De PP; Chow A; Tambyah PA; Lye DC
PLoS One; 2016; 11(4):e0153696. PubMed ID: 27104951
[TBL] [Abstract][Full Text] [Related]
12. Antimicrobial susceptibility of clinical Enterobacteriaceae isolates at the emergency department in a regional hospital: A threat of extended spectrum beta-lactamase-producers among nursing home residents.
Liu HC; Hung YP; Lin HJ; Liu HC; Lee JC; Wu YH; Li CW; Li MC; Ko WC
J Microbiol Immunol Infect; 2016 Aug; 49(4):584-90. PubMed ID: 26692184
[TBL] [Abstract][Full Text] [Related]
13. The impact of the increased use of piperacillin/tazobactam on the selection of antibiotic resistance among invasive Escherichia coli and Klebsiella pneumoniae isolates.
Lee J; Oh CE; Choi EH; Lee HJ
Int J Infect Dis; 2013 Aug; 17(8):e638-43. PubMed ID: 23523562
[TBL] [Abstract][Full Text] [Related]
14. Piperacillin-Tazobactam-Resistant/Third-Generation Cephalosporin-Susceptible Escherichia coli and Klebsiella pneumoniae Isolates: Resistance Mechanisms and In vitro-In vivo Discordance.
Abdelraouf K; Chavda KD; Satlin MJ; Jenkins SG; Kreiswirth BN; Nicolau DP
Int J Antimicrob Agents; 2020 Mar; 55(3):105885. PubMed ID: 31923568
[TBL] [Abstract][Full Text] [Related]
15. Piperacillin/tazobactam in the treatment of Klebsiella pneumoniae infections in neonates.
Pillay T; Pillay DG; Adhikari M; Sturm AW
Am J Perinatol; 1998 Jan; 15(1):47-51. PubMed ID: 9475688
[TBL] [Abstract][Full Text] [Related]
16. Use of cefepime for the treatment of infections caused by extended spectrum: beta-lactamase-producing Klebsiella pneumoniae and Escherichia coli.
Arya SC; Agarwal N; Solanki BS; Agarwal S
Singapore Med J; 2007 Jun; 48(6):600-1. PubMed ID: 17538771
[No Abstract] [Full Text] [Related]
17. Outcomes associated with empiric cefepime for bloodstream infections caused by ceftriaxone-resistant, cefepime-susceptible Escherichia coli and Klebsiella pneumoniae.
Frescas BE; McCoy CM; Kirby J; Bowden R; Mercuro NJ
Int J Antimicrob Agents; 2023 May; 61(5):106762. PubMed ID: 36804369
[TBL] [Abstract][Full Text] [Related]
18. Association of piperacillin/tazobactam MIC and mortality in a cohort of ceftriaxone-resistant Escherichia coli bloodstream infections treated with piperacillin/tazobactam and carbapenems: a multicentric propensity score-weighted observational cohort study.
Rando E; Salvati F; Sangiorgi F; Catania F; Leone E; Oliva A; Di Gennaro F; Fiori B; Cancelli F; Figliomeni S; Bobbio F; Sacco F; Bavaro DF; Diella L; Belati A; Saracino A; Mastroianni CM; Fantoni M; Murri R
J Antimicrob Chemother; 2024 Feb; 79(2):453-461. PubMed ID: 38169441
[TBL] [Abstract][Full Text] [Related]
19. Antimicrobial Activity of High-Proportion Cefepime-Tazobactam (WCK 4282) against a Large Number of Gram-Negative Isolates Collected Worldwide in 2014.
Sader HS; Castanheira M; Mendes RE; Flamm RK; Jones RN
Antimicrob Agents Chemother; 2017 Apr; 61(4):. PubMed ID: 28137811
[TBL] [Abstract][Full Text] [Related]
20. Impact of the MIC of piperacillin-tazobactam on the outcome of patients with bacteremia due to extended-spectrum-β-lactamase-producing Escherichia coli.
Retamar P; López-Cerero L; Muniain MA; Pascual Á; Rodríguez-Baño J;
Antimicrob Agents Chemother; 2013 Jul; 57(7):3402-4. PubMed ID: 23612190
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
